Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
Nelfinavir mesylate by Pfizer for Relapsed Multiple Myeloma: Likelihood of Approval
Nelfinavir mesylate is under clinical development by Pfizer and currently in Phase I for Relapsed Multiple Myeloma. According to GlobalData,...